Page last updated: 2024-11-12

nb 506

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

NB 506: an indolocarbazole antitumor agent; structure given in first source; a DNA topoisomerase I inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9915861
CHEMBL ID2074831
SCHEMBL ID5481070
MeSH IDM0244090

Synonyms (15)

Synonym
CHEMBL2074831
SCHEMBL5481070
6-n-formylamino-12,13-dihydro-1,11-dihydroxy-13-(beta-d-glucopyranosyl)-5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione
nb-506
n-[5,21-dihydroxy-12,14-dioxo-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaen-13-yl]formamide
formamide, n-(12-.beta.-d-glucopyranosyl-5,7,12,13-tetrahydro-1,11-dihydroxy-5,7-dioxo-6h-indolo(2,3-a)pyrrolo(3,4-c)carbazol-6-yl)-
6-n-formylamino-12,13-dihydro-1,11-dihydroxy-13-(.beta.-d-glucopyranosyl) 5h-indolo (2,3-a)pyrrolo (3,4-c)carbazole-5,7(6h)-dione
n-(12-.beta.-d-glucopyranosyl-5,7,12,13-tetrahydro-1,11-dihydroxy-5,7-dioxo-6h-indolo(2,3-a)pyrrolo(3,4-c)carbazol-6-yl)formamide
unii-q7sf8h5tf6
n-(12-beta-d-glucopyranosyl-5,7,12,13-tetrahydro-1,11-dihydroxy-5,7-dioxo-6h-indolo(2,3-a)pyrrolo(3,4-c)carbazol-6-yl)formamide
151069-12-4
q7sf8h5tf6 ,
6-n-formylamino-12,13-dihydro-1,11-dihydroxy-13-(beta-d-glucopyranosyl) 5h-indolo (2,3-a)pyrrolo (3,4-c)carbazole-5,7(6h)-dione
nb 506
formamide, n-(12-beta-d-glucopyranosyl-5,7,12,13-tetrahydro-1,11-dihydroxy-5,7-dioxo-6h-indolo(2,3-a)pyrrolo(3,4-c)carbazol-6-yl)-

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Cytotoxicity measurements performed with various human cancer cell lines (HCT-116, DLD-1, MKN-45) indicate that the newly designed drug is 3 to 4 times more toxic to colon and gastric cancer cells than NB-506."( Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
Bailly, C; Chaires, JB; Colson, P; Houssier, C; Nishimura, S; Ohkubo, M; Qu, X; Yoshinari, T, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID681276TP_TRANSPORTER: intracellular accumulation in LY and LY/NR2 cells2001Cancer research, Apr-01, Volume: 61, Issue:7
Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's22 (78.57)18.2507
2000's6 (21.43)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.64 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index4.00 (0.95)

This Compound (18.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (96.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]